Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

1. CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.Frontiers in immunology · 2026
   Pooled it
2. Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.Journal for immunotherapy of cancer · 2026
   Trial
3. Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.Cancer research communications · 2026
   Trial
4. Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.Nature communications · 2025
   Trial
5. A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
   Trial
6. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).Journal for immunotherapy of cancer · 2023
   Trial
7. Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.Breast cancer research and treatment · 2023
   Trial
8. CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026
   Review
9. Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling.International journal of molecular sciences · 2026
   Review
10. CD8 T lymphocytes deploy embryonic cell cycle control mechanisms for rapid cell proliferation.EMBO reports · 2026
    Article
11. Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.Pharmaceutics · 2026
    Article
12. CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
13. Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026
    Review
14. LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.Science advances · 2026
    Article
15. Cell Cycle Sensing Shapes Human T Cell Fate and Exhaustion Programs.bioRxiv : the preprint server for biology · 2026
    Article
16. CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.Oncogene · 2026
    Article
17. The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.Translational cancer research · 2026
    Review
18. MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research · 2026
    Article
19. Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
20. Revisiting the Immune Frontier in Soft Tissue Sarcomas.Current oncology reports · 2026
    Review

39 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

24 authors at 5 institutions in 2 countries.

Funding

Abstract

Indexed as